澳大利亚治疗用品管理局(TGA)发布通告,苯青霉素注射剂产品将基于商业原因逐步退出市场。停产计划将自11月30日起开始实施,首当其冲的将是600毫克规格的产品。此举意味着该规格的供应将逐步减少并最终停止。后续其他规格产品的停产安排,预计将根据商业评估结果进一步公布。
澳大利亚治疗用品管理局(TGA)发布通告,苯青霉素注射剂产品将基于商业原因逐步退出市场。停产计划将自11月30日起开始实施,首当其冲的将是600毫克规格的产品。此举意味着该规格的供应将逐步减少并最终停止。后续其他规格产品的停产安排,预计将根据商业评估结果进一步公布。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.